- Home
- SLXN vs MYNZ Comparison
SLXN vs MYNZ Comparison
Compare SLXN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- MYNZ
- Stock Information
- Founded
- SLXN 2008
- MYNZ 2021
- Country
- SLXN Israel
- MYNZ Germany
- Employees
- SLXN N/A
- MYNZ N/A
- Industry
- SLXN
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SLXN
- MYNZ Health Care
- Exchange
- SLXN NYSE
- MYNZ Nasdaq
- Market Cap
- SLXN 6.9M
- MYNZ 8.0M
- IPO Year
- SLXN N/A
- MYNZ 2021
- Fundamental
- Price
- SLXN $0.95
- MYNZ $2.08
- Analyst Decision
- SLXN Strong Buy
- MYNZ Buy
- Analyst Count
- SLXN 1
- MYNZ 2
- Target Price
- SLXN $5.00
- MYNZ $14.00
- AVG Volume (30 Days)
- SLXN 1.2M
- MYNZ 92.3K
- Earning Date
- SLXN 05-13-2025
- MYNZ 06-17-2025
- Dividend Yield
- SLXN N/A
- MYNZ N/A
- EPS Growth
- SLXN N/A
- MYNZ N/A
- EPS
- SLXN N/A
- MYNZ N/A
- Revenue
- SLXN N/A
- MYNZ $893,991.00
- Revenue This Year
- SLXN N/A
- MYNZ $26.06
- Revenue Next Year
- SLXN N/A
- MYNZ $4.97
- P/E Ratio
- SLXN N/A
- MYNZ N/A
- Revenue Growth
- SLXN N/A
- MYNZ N/A
- 52 Week Low
- SLXN $0.58
- MYNZ $1.92
- 52 Week High
- SLXN $41.85
- MYNZ $34.00
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- MYNZ 38.07
- Support Level
- SLXN N/A
- MYNZ $1.93
- Resistance Level
- SLXN N/A
- MYNZ $2.10
- Average True Range (ATR)
- SLXN 0.00
- MYNZ 0.16
- MACD
- SLXN 0.00
- MYNZ 0.04
- Stochastic Oscillator
- SLXN 0.00
- MYNZ 30.39
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.